Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 5/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.38 |
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | FPR2 | P25090 | 4/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921742 | 0.90 | JAK1 (0.39) | JAK1JAK2JAK3TYK2BRD4 | |
| SCHEMBL9918533 | 0.82 | MAP3K11 (0.41) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL9918534 | 0.75 | TSHR (0.35) | JAK1JAK2JAK3TYK2CYP2D6 | |
| SCHEMBL9921664 | 0.73 | MAP3K11 (0.41) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL9918540 | 0.71 | EGFR (0.42) | JAK1JAK2JAK3BRD4SLC2A1 | |
| SCHEMBL18421083 | 0.68 | EGFR (0.41) | EGFR | |
| SCHEMBL9921770 | 0.67 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL9918554 | 0.67 | PDE3B (0.40) | JAK1JAK2JAK3 | |
| SCHEMBL9921741 | 0.67 | ESR1 (0.38) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL9918552 | 0.66 | HTT (0.39) | JAK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.